# EDGAR Filing Document

**Accession Number:** 0001866390
**File Stem:** 0001866390-23-000038
**Filing Date:** 2023-1
**Character Count:** 46020
**Document Hash:** 23b430343e11fc8ffa1e043f44850f46
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001866390-23-000038.hdr.sgml**: 20230112

**ACCESSION NUMBER**: 0001866390-23-000038

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 33

**CONFORMED PERIOD OF REPORT**: 20230112

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230112

**DATE AS OF CHANGE**: 20230112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Babylon Holdings Ltd
- **CENTRAL INDEX KEY:** 0001866390
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40952
- **FILM NUMBER:** 23524886

**BUSINESS ADDRESS:**
- **STREET 1:** 2500 BEE CAVE ROAD
- **STREET 2:** BLDG 1, STE 400
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746
- **BUSINESS PHONE:** 512-967-3787

**MAIL ADDRESS:**
- **STREET 1:** 2500 BEE CAVE ROAD
- **STREET 2:** BLDG 1, STE 400
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746

?xml version="1.0" ? bbln-20230112

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**___________________________________**

**FORM 8-K**

**___________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**January 12, 2023**

Date of Report (date of earliest event reported)

**___________________________________**

**Babylon Holdings Limited**

(Exact name of registrant as specified in its charter)

**___________________________________**

---

| | | |
|:---|:---|:---|
| **Bailiwick of Jersey, Channel Islands**<br>(State or other jurisdiction of <br>incorporation) | **001-40952**<br>(Commission File Number) | **98-1638964**<br>(IRS Employer Identification No.) |
| **2500 Bee Cave Road**<br>**Building 1 - Suite 400**<br>**Austin, TX**  |  | **78746** |
| (Address of principal executive offices) |  | (Zip Code) |
| **(512) 967-3787** | **(512) 967-3787** | **(512) 967-3787** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
| **Not Applicable** | **Not Applicable** | **Not Applicable** |
| (Former name or former address, if changed since last report) | (Former name or former address, if changed since last report) | (Former name or former address, if changed since last report) |

---

**___________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| Class A ordinary shares, par value $0.001056433113 per share | BBLN | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;☒

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

To the extent the information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 and Exhibit 99.2) relates to a completed fiscal period, such information is incorporated by reference into this Item 2.02.

**Item 7.01 Regulation FD Disclosure.** 

On January 12, 2023, the Founder and Chief Executive Officer, Ali Parsa, and Chief Financial Officer, David Humphreys, of Babylon Holdings Limited ("Babylon") will present at the 41st Annual J.P. Morgan Healthcare Conference, during a live presentation at 10:30 a.m. Pacific Time. A copy of the presentation slides, which will be discussed at the conference, is attached as Exhibit 99.1 to this Form 8-K.

In addition, on January 12, 2023, Babylon issued a press release providing updates to its previous guidance concerning 2022 full year revenue and 2022 Adjusted EBITDA under International Financial Reporting Standards (IFRS), and additional updates. A copy of the press release is attached as Exhibit 99.2 to this Form 8-K and incorporated by reference herein. These updates will be discussed during Babylon's presentation at the conference.

The live audio webcast of the presentation will be available on the "Events" page of the Investors section of Babylon's website. The replay will remain available for 30 days following the event.

The press release, presentation, and the other information in Items 2.02 and 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 and Exhibit 99.2) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

------

**Item 9.01 - Financial Statements and Exhibits**

(d) Exhibits:

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Description</u> |
| <u>[99.1](ex991jpmpresentationslid.htm)</u> | <u>[J.P. Morgan Healthcare Conference Presentation Slides, dated January 12, 2023](ex991jpmpresentationslid.htm)</u> |
| <u>[99.2](ex992pressrelease.htm)</u> | <u>[Press Release, dated January 12, 2023](ex992pressrelease.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2023

---

| | |
|:---|:---|
| **Babylon Holdings Limited** | **Babylon Holdings Limited** |
| By: | /s/ David Humphreys |
| Name: | David Humphreys |
| Title: | Chief Financial Officer |

---

## Exhibit 99.1

![](ex991jpmpresentationslid001.jpg)

1 Putting accessible and affordable quality healthcare in the hands of every person on Earth J.P. Morgan 41st Annual Healthcare Conference January 12, 2023

------

![](ex991jpmpresentationslid002.jpg)

Disclaimer Information Sources The information herein is derived from various internal and external sources. Unless otherwise indicated, information contained in this presentation concerning Babylon's industry and the regions in which it operates, including Babylon's general expectations and market position, market opportunity, market share and other management estimates, is based on information obtained from various independent publicly available sources and reports provided to us, and other industry publications, surveys and forecasts. We have not independently verified the accuracy or completeness of any third-party information. Similarly, internal surveys, industry forecasts and market research, which we believe to be reliable based upon our management's knowledge of the industry, have not been independently verified. While we believe that the market data, industry forecasts and similar information included in this presentation are generally reliable, such information is inherently imprecise. In addition, assumptions and estimates of our future performance and growth objectives and the future performance of our industry and the markets in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those discussed under the heading "Forward-Looking Statements" above and in our filings with the SEC. This presentation contains references to trademarks, trade names and service marks belonging to other entities. Solely for convenience, trademarks, trade names and service marks referred to in this presentation may appear without the® or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor does not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by any other companies. Use of Non-IFRS Financial Measures This presentation includes certain financial measures to evaluate Babylon's projected financial and operating performance, and measures calculated based on these measures, including Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin, that are not prepared in accordance with IFRS. EBITDA is defined as profit (loss) for the period, adjusted for finance costs and income, depreciation and amortization, and tax provision or benefit. Adjusted EBITDA is defined as profit (loss) for the period, adjusted for finance costs and income, depreciation and amortization, tax provision or benefit, impairment expenses, change in fair value of warrant liabilities, loss on settlement of warrants, share-based compensation, foreign exchange gain or loss, restructuring and other one-time benefit arrangements and gain or loss on sale of subsidiaries. Loss for the period is the most directly comparable IFRS measure to Adjusted EBITDA. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Total revenue for the corresponding period. IFRS Loss for the period margin is the most directly comparable IFRS measure to Adjusted EBITDA Margin. Medical Loss Ratio and Medical Margin are derived from amounts presented in Babylon's Statement of Profit and other Comprehensive Loss for the applicable period, included in our reports filed with the SEC. We believe that EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin are useful metrics for investors to understand and evaluate our operating results and ongoing profitability because they permit investors to evaluate our recurring profitability from our ongoing operating activities. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin have certain limitations, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under IFRS. We caution you that amounts presented in accordance with our definitions of EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin may not be comparable to similar measures disclosed by other companies, because some companies calculate EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin differently or not at all, limiting their usefulness as direct comparative measures. A reconciliation of Adjusted EBITDA and other non-IFRS financial measures to the most directly comparable IFRS measures, and calculation of certain non-IFRS measures, is included at the end of this presentation. Any FY 2022 and Q4 2022 results, including estimated Medical Margins, described in this presentation are preliminary, unaudited and subject to change in connection with the completion of Babylon's financial closing process and the preparation of its audited financial statements for 2022. Additional Information and Where to Find It Babylon Holdings Limited ("Babylon") is subject to the informational reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We file reports and other information with the Securities and Exchange Commission (the "SEC") under the Exchange Act. Our SEC filings are available over the Internet at the SEC's website at www.sec.gov. Forward-Looking Statements This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. When used in this presentation, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward- looking statements. These forward-looking statements include, without limitation, information concerning Babylon's possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment and potential growth opportunities. These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Babylon's management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to: our future financial and operating results and ability to generate profits in the future and our timeline to profitability; that we may require additional financing and our ability to obtain additional financing on favorable terms; our ability to sell the Meritage Medical Network/Independent Physician Association business, including the timing of the sale and the sale price; the impact of our recently completed reverse share split on the price and trading market for our Class A ordinary shares; if we fail to comply with the continued listing standards and rules of the New York Stock Exchange (the "NYSE"), the NYSE may delist our Class A ordinary shares; uncertainties related to our ability to continue as a going concern; our ability to successfully execute our planned cost reduction actions and realize the expected cost savings; the growth of our business and organization; risks associated with impairment of goodwill and other intangible assets; our failure to compete successfully; our ability to renew contracts with existing customers, and risks of contract renewals at lower fee levels, or significant reductions in members, pricing or premiums under our contracts due to factors outside our control; our dependence on our relationships with physician-owned entities; our ability to maintain and expand a network of qualified providers; our ability to increase engagement of individual members or realize the member healthcare cost savings that we expect; a significant portion of our revenue comes from a limited number of customers; the uncertainty and potential inadequacy of our claims liability estimates for medical costs and expenses; risks associated with estimating the amount and timing of revenue recognized under our licensing agreements and value-based care agreements with health plans; risks associated with our physician partners' failure to accurately, timely and sufficiently document their services; risks associated with inaccurate or unsupportable information regarding risk adjustment scores of members in records and submissions to health plans; risks associated with reduction of reimbursement rates paid by third-party payers or federal or state healthcare programs; risks associated with regulatory proposals directed at containing or lowering the cost of healthcare, including the ACO REACH model; immaturity and volatility of the market for telemedicine and our unproven digital-first approach; our ability to develop and release new solutions and services; difficulty in hiring and retaining talent to operate our business; risks associated with our international operations, economic uncertainty, or downturns; the impact of COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business; risks associated with foreign currency exchange rate fluctuations and restrictions; and the other risks and uncertainties identified in Babylon's Annual Report on Form 20-F filed with the SEC on March 30, 2022, and in other documents filed or to be filed by Babylon with the SEC and available at the SEC's website at www.sec.gov. Babylon cautions that the foregoing list of factors is not exclusive and cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, Babylon does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this presentation. 2

------

![](ex991jpmpresentationslid003.jpg)

3 Babylon is a purpose-built, digital-first platform for delivering value-based care at scale Digital-first, AI-led, Scalable Model Comprehensive, Integrated, Cost Effective Care Intrinsically Value-based • Powers rapid scaling and engagement of new populations • Intelligent, data-driven care empowering clinicians and patients • VBC native – capabilities (technologies, products, and services) built from ground up • VBC model drives strong alignment with customers, members, providers, and partners • Uniquely end-to-end – digital-only, virtual, in-person • Full longitudinal member coverage – primary and secondary care, acute and chronic care 50%+ member interactions via technology platform(1) 85% primary care consultations entirely virtual(2) 1,500+ global, multispecialty provider network(3) 90%+ of which Babylon directly employs in the US ~271K VBC members in the US(4) 12ppt Estimated medical margin improvement in digital-first mature VBC cohorts(5) Notes: (1) This metric was calculated using Babylon data from September 2021 to December 2021 from the following regions: US, UK, Rwanda, KS A, Canada and SE Asia. An 'interaction' takes place if a user engages with one of the following Babylon products/services: Consultation, Symptom Checker, Health Check, Health Assessment or Monitor. (2) Based on Babylon GP at Hand Internal data. (3) Babylon Internal Data as of December 16, 2022. (4) Under contract as of September 30, 2022. (5) Medical Margin is defined as 1 minus Medical Loss Ratio. Medical Loss Ratio defined as the absolute value of Claims Expense divided by VBC revenue. Data for NY, MS, GA cohorts from Q3 '21 to Q4 '22 YTD.

------

![](ex991jpmpresentationslid004.jpg)

Global Footprint 15 Countries where Babylon Technology is Deployed(1) 16 Languages(2) Babylon at a Glance Clinical & Technology 4 Scale Financial 3 Countries where Babylon Delivers its own Clinical Services 10M+ Lives with Access to Babylon Clinical Services ~271K US VBC Members(3) 5.2M Patient Consultations & AI Interactions(4) 95% Of Members Ascribed Babylon a 4-5 Star Rating(5) 1,500+ Global Provider Network $1.05B+ Estimated Annual Revenue in FY22(6) 4.8x YoY Growth in VBC Revenue from Q3 '21 to Q3 '22(1) 45ppt YoY Adjusted EBTIDA margin improvement from Q3 '21 to Q3 '22(1) $500M+ Invested in Babylon's Technology Notes: (1) As per the Form 6-K filed with the SEC on November 10, 2022. (2) As per Form 20-F filed with the SEC on March 28, 2022 (3) Under contract as of September 30, 2022. (4) 2021 Babylon member interactions. (5) Based on patient surveys in the UK, US, Rwanda and Canada for 2020-2021. (6) Includes any revenue from discontinued operations in IFRS as per January 12, 2023 press release filed with the SEC on Form 8-K on January 12, 2023. This financial result is preliminary, unaudited and subject to change in connection with the completion of Babylon's financial closing process and the preparation of its audited financial statements for 2022, which will be reported in U.S. GAAP.

------

![](ex991jpmpresentationslid005.jpg)

------

![](ex991jpmpresentationslid006.jpg)

Babylon's digital-first model influences care at all stages of the member journey and is scalable across all populations Notes: Some features or elements of features may be under active development, have not been commercialized and we cannot guarantee if / when the product will be delivered to members. Real-Time Insights Engagement Monitoring (Reward, Alert, Early Intervention) 24/7 Health AssistancePersonal Health Graph AI Advisor Digital-First Complex Care (Including Medicare) Digital-First Pharmacy Hospitalization Support Local In-Person Network Virtual Multi- Specialty Care 6

------

![](ex991jpmpresentationslid007.jpg)

Our care model steers members to the most clinically-appropriate and resource-efficient care setting to optimize outcomes and savings 7 Hospitalization Digital Engagement & Self-Care Non-Clinical \| Care Navigation Clinical \| Virtual Local \| In-Person $'s (1) $$$'s Millions (2) Thousands Highly-Scalable and Automated to Maximize Access and Optimize Cost 24/7 Concierge for Appropriate Member Steerage Cost-Effective, Resource- Efficient Multispecialty Virtual Care Expansive Network for In- Person Care (Labs/Dx, Clinics, Rx) High-Acuity & Complex Care Support Notes: (1) Cost of care. (2) Population size.

------

![](ex991jpmpresentationslid008.jpg)

We have assembled a comprehensive global provider network to deliver the highest quality care United States United Kingdom Licensed Technology Footprint Rwanda 870+ Virtual Providers in Network 1M+ Appointments delivered in 12 months(5) 45% 34% 21% PCPs Specialists Clinical Support 350+ Virtual Providers in Network 30% Of Adult Population in Rwanda registered since 2016 34% 55% 11% PCPs Specialists Clinical Support 11 Country Software Licensing Agreement in Southeast Asia + Canada, UK, and the US 14 Epidemiological Models Operating and Utilized 8 1,500+ Global Provider Network Providers Employed in the US 90%+ Specialties(1) 20 State US Footprint(2) 50 Of Members Reported Positive Clinical Impact(3) 82% Of Members Give Babylon a 4-5 Star Rating(4) 95% 270+ Virtual Providers in Network >50% Multi-State Licensed 32% 37% 31% PCPs Specialists Clinical Support Notes: (1) Specialties accessible through our providers and Babylon's peer-to-peer provider network, Sitka. (2) Babylon's multi-state licensed clinicians can practice in 50 states. (3) Babylon Voice of the Patient Survey - members reporting maintained or improved health after a Babylon encounter, Nov '22 results in the US. (4) Based on patient surveys in the UK, US, Rwanda and Canada for 2020-2021. (5) Babylon UK Operations Internal Data from Oct '21 to Oct '22.

------

![](ex991jpmpresentationslid009.jpg)

Our AI-led platform has been purpose-built to maximize functionality, utilize data intelligently, drive patient engagement, and enhance operational efficiency… 9 Depth and Breadth of Functions & Capabilities Rich, Patient Experience-Led Applications Data & AI-Powered Insights Embedded Across the Platform Comprehensive Clinical Service Delivery • Enterprise-grade, white-labeled for B2B clients globally • Localized and deployed in 15 countries • EMR and third party integrations • Deployed in various payor-partner apps and services across national health systems and payor organizations • Millions with access to Babylon's technology globally via web, app, phone • Product development guided by significant volume of member feedback • Vast array of configurations in patient profiles, appointment types, patient journey • 100+ data sources drive personalized insights • Predicted health acuity scores for 170K+ members, enabling early intervention(1) • Cutting-edge AI research recognized for its excellence • Automated 55% of post-consultation tasks, enabling clinicians to focus on patient care • AI designed for clinical decision support • ~80% average recall achieved by our AI vs. 84% recall by doctors(2) ~250 Technology employees globally $500M+ Invested in Technology 24 Patents granted in the US/UK ~30 Peer Reviewed Publications Notes: (1) Babylon Internal Data, as of Dec '22. (2) A Comparison of Artificial Intelligence and Human Doctors for the Purpose of Triage and Diagnosis (2020). Recall (also called sensitivity) is the proportion of relevant diseases that are included in the differential.

------

![](ex991jpmpresentationslid010.jpg)

Independent analysis has proven the efficacy of our digital-first model in the UK; we are seeing similar leading indicators of progress in the US Notes: (1) Based on an evaluation by Ipsos Mori of NHS data, comparing newly registered patients at our Babylon GP at Hand (NHS) service to patients newly registered at London GP Practices. London, UK is used as the comparator as Babylon GP at Hand is based in this area. (2) Based on UK data, specifically for our Babylon GP at Hand (NHS) service. Babylon GP at Hand acute care cost per weighted patient in 2019/20 was compared to the North West London average in 2019/20, using NHS funding formulae to account for age, sex and other factors influencing health need. North West London is used as the comparator as Babylon GP at Hand is based in this area. (3) Based on data from Georgia and Mississippi cohorts. 10 In-Person Care Acute Care Utilization Member Engagement 22% (6%) Likelihood of ER visit 12-months prior to joining Babylon Likelihood of ER visit 12-months after joining Babylon 25%+ Reduction in ER Visit Likelihood(1) (28%) ~35% Acute Care Cost Savings(2) Over 60% Reduction in Likelihood of NHS 111 Call(1) £714 £749 £468 £635 Core Services Weighting Adapted Core Weighting Services Babylon GP at HandNorth West London Average (34%) (15%) 62% (1%) Likelihood of calling NHS 111 12-months prior to joining Babylon Likelihood of calling NHS 111 12-months after joining Babylon (63%) 50% Reduction in Depression and Anxiety which is a Leading Indicator for Reduced Physical Care Costs 30% Reduction of Inpatient Admissions in our Longest- Tenured Contract 25% Engagement of High Risk Members in the First 6 Months of Contract (3)

------

![](ex991jpmpresentationslid011.jpg)

We are seeing strong medical margin improvement in our digital-first cohorts… 0% 5% 10% 15% 20% 25% 30% 35% 0 10 20 30 80 90 100 110 25.5%(4) 30.5% 26.6% 13.6% 40 50 60 70 Weeks from Launch % of High-Risk Members Signed Up Since Launch(3)2021 Digital-First VBC Cohort(1) Medical Margin(2) (4.1%) (3.7%) (2.8%) 2.7% 7.6% Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Notes: (1) Includes digital-first VBC deals that went live in 2021 across New York, Georgia, and Mississippi. (2) Medical Margin is defined as 1 minus Medical Loss Ratio. Medical Loss Ratio is defined as the absolute value of Claims Expense divided by VBC revenue. (3) Representative of unique members on the platform, recalculated for 30 September 2022. (4) Missouri data from Weeks 1 to 10 from launch taken as straight line average due to incomplete data. 11 …and our clinical performance continues to accelerate as we learn from each VBC contract

------

![](ex991jpmpresentationslid012.jpg)

Our business model is modular to best meet client needs and has three revenue streams Product Offerings Selected CustomersFee Model Revenue Breakdown(1) Software Licensing Insight Goals Plans Monitor Steerage Healthcheck Health Assessment Digital Care Plan Care Monitor Digital Triage License Our Technology 19% $s PMPM Access Fee + Visit Fee Fee for Service Plus Virtual Consultations Multidisciplinary Care 13% $10sCare Navigation Notes: (1) Represents 2021A revenue breakdown. 12 Take Patient Budgets Capture Cost Savings Value-Based Care 68% $1,000sHospitalization Digital Engagement & Self-Care Non-Clinical \| Care Navigation Clinical \| Virtual Local \| In-Person

------

![](ex991jpmpresentationslid013.jpg)

Our Care Model is Delivering Strong Revenue and VBC membership Value-Based Care MembershipRevenue We continue to deliver strong growth… Sources: 2021 20-F filed 03/28/2022 and Form 6-K filed on November 10, 2022. Notes: (1) : Actual revenue for 2020 and 2021 in IFRS. Estimated revenue for 2022 on both an IFRS and U.S. GAAP basis, including any revenue relating to discontinued operations. As per the January 12, 2023 press release filed with the SEC on Form 8-K on January 12, 2023. This financial result is preliminary, unaudited and subject to change in connection with the completion of Babylon's financial closing process and the preparation of its audited financial statements for 2022, which will be reported in U.S. GAAP. (1) 124% CAGR 66,000 167,000 271,000 12/31/2020 12/31/2021 9/30/2022 13 $79 $323 $1.05B - $1.1B 2020A 2021A 2022E 268% CAGR $1.05B+(1) $79M $323M

------

![](ex991jpmpresentationslid014.jpg)

…while proactively diversifying the risk profile of our member base with a focus on Medicare and commercial lives Notes: (1) Other includes certain revenue generating items not included within Medicaid, Medicare and commercial categories such as Higi revenue and third party admin fee revenue. 69% 68% 44% 58% 71% 60% 59% 55% 31% 32% 33% 28% 19% 36% 37% 41% 22% 13% 8% 3% 3% 3% 1% 1% 2% 1% 1% 1% $27 $27 $39 $56 $99 $247 $244 $268 Q4-2020 Q1-2021 Q2-2021 Q3-2021 Q4-2021 Q1-2022 Q2-2022 Q3-2022 Medicaid Medicare Commercial Other 4.8x YoY VBC Revenue growth VBC Revenue Mix(1) $M • Proactively diversifying member mix to increase proportion of higher PMPM and "easier-to- engage" Medicare and commercial populations • Medicare and commercial populations contributed ~44% of total VBC revenue in Q3 2022 (1) 14

------

![](ex991jpmpresentationslid015.jpg)

We have consistently enhanced our margin profile through scale and successful execution of cash runway enhancement measures Revenue & Adj. EBITDA Margin 187ppt margin improvement since Q3-20 whilst growing revenue by ~18.3x Notes: (1) For greater detail, refer to the Appendix for a reconciliation of Adjusted EBITDA and the calculation of other non-IFRS measures. Revenue and Adjusted EBITDA (IFRS) figures exclude $28.4m of one-off upfront revenue recognition in connection with a software licensing arrangement in Q1 2021. $16 $41 $43 $57 $74 $120 $266 $265 $289 (206%) (91%) (77%) (86%) (64%) (61%) (27%) (26%) (19%) Q3-2020 Q4-2020 Q1-2021 Q2-2021 Q3-2021 Q4-2021 Q1-2022 Q2-2022 Q3-2022 Revenue Adj. EBITDA Margin $M (1) 15

------

![](ex991jpmpresentationslid016.jpg)

Preliminary Results for 2022: Beating Expectations 16 Notes: (1) These numbers including any revenue from discontinued operations are in IFRS as per January 12, 2023 press release filed with the SEC on Form 8-K on January 12, 2023. This financial result is preliminary, unaudited and subject to change in connection with the completion of Babylon's financial closing process and the preparation of its audited financial statements for 2022, which will be reported in U.S. GAAP. Our 2022 revenue is expected to exceed $1.05(1) billion on both an International Financial Reporting Standards (IFRS) and U.S. GAAP basis (exceeding the lower end of our previous guidance of $1.05 to $1.1 billion). Our 2022 IFRS Adjusted EBITDA is expected to beat our previous guidance of $(270)(1) million or less. In July 2022 we announced cost reductions expected to deliver $100 million in yearly savings. As a result of additional cost saving measures, we expect to deliver an additional 25% in cost reductions on an annualized basis. We expect the proceeds from the planned sale of our IPA business in California in early 2023 to fund Babylon to profitability.

------

![](ex991jpmpresentationslid017.jpg)

Thank you!

------

![](ex991jpmpresentationslid018.jpg)

Appendix

------

![](ex991jpmpresentationslid019.jpg)

Reconciliation of Adjusted EBITDA and Other Non-IFRS Measures Note: We are not able to reconcile projected 2022 Adjusted EBITDA or 2022 Adjusted EBITDA Margin to their respective most directly comparable IFRS measures as we are not able to forecast IFRS loss for the period on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in predicting certain items that affect IFRS loss for the period, including, but not limited to, changes in fair value of warrant liabilities, impairment expense, share-based compensation, restructuring and other one-time benefits, foreign exchange gains or losses and gains and losses on sale of subsidiaries. Adjusted EBITDA should not be used to predict IFRS loss for the period as the difference between the two measures is variable and may be significant. (2) $000s Q3-2020 Q4-2020 Q1-2021 Q2-2021 Q3-2021 Q4-2021 Q1-2022 Q2-2022 Q3-2022 Loss for the period ($37,986) ($59,230) ($10,847) ($64,875) ($65,975) ($232,815) ($91,357) ($157,079) ($89,891) Adjustments to calculate EBITDA: Depreciation and amortization 3,072 4,956 5,848 7,474 8,823 12,859 9,458 11,944 7,477 Finance costs and income 478 879 978 1,237 2,049 9,701 6,373 9,688 8,617 Tax provision / (benefit) 63 1,639 8 (2,501) 7 1,012 9 199 280 EBITDA ($34,373) ($51,756) ($4,013) ($58,665) ($55,096) ($209,243) ($75,517) ($135,248) ($73,517) Adjustments to calculate Adjusted EBITDA: Share-based compensation $2,019 $7,105 $2,802 $9,542 $7,241 $26,722 $8,402 $10,564 $8,955 Change in fair value of warrant liabilities — — — — — (27,811) (5,575) (10,791) (1,143) Loss on settlement of warrants — — — — — — — 2,375 22 Gain on remeasurement of equity interest — — — — — (10,495) — — — Gain on sale of subsidiary — — (3,917) — — — — — — Impairment expense — — — — — — — 53,224 1,400 Restructuring and other one-time benefit arrangements — 6,404 — — — 941 — 3,848 5,135 Exchange (gain) / loss (259) 949 573 (482) 396 (1,355) 447 7,350 4,848 Recapitalization transaction expense — — — — — 148,722 — — — Adj. EBITDA ($32,613) ($37,298) ($4,555) ($49,605) ($47,459) ($72,519) ($72,243) ($68,678) ($54,300) Total revenue $15,811 $40,958 $71,293 $57,478 $74,462 $119,688 $266,446 $265,362 $288,898 IFRS Loss for the Period Margin % (240%) (145%) (15%) (113%) (89%) (195%) (34%) (59%) (31%) Adjusted EBITDA Margin % (206%) (91%) (6%) (86%) (64%) (61%) (27%) (26%) (19%) Value-based care revenue — $26,038 $27,259 $39,133 $55,715 $98,745 $246,575 $244,098 $267,686 Claims expense — — (23,917) (40,384) (51,298) (104,026) (247,552) (238,764) (264,283) Medical Loss Ratio % — — 88% 103% 92% 105% 100% 98% 99% Medical Margin % — — 12% (3%) 8% (5%) (0%) 2% 1% 19

------

## Exhibit 99.2

Babylon Delivers Strong 2022 Results, Beating Expectations

**JANUARY 12, 2023** - AUSTIN, Texas and LONDON – (BUSINESS WIRE) – Babylon Holdings Limited (NYSE: BBLN) ("Babylon" or the "Company") today confirmed that its revenue for the year ended December 31, 2022 is expected to exceed $1.05 billion on both a U.S. GAAP and International Financial Reporting Standards (IFRS) basis, including revenue from the IPA business in California. Babylon also expects to beat its previous IFRS Adjusted EBITDA guidance of $(270) million or less for 2022. These financial results are preliminary, unaudited and subject to change in connection with the completion of Babylon's financial closing process and the preparation of its audited financial statements for 2022.

In July 2022, Babylon announced cost reductions expected to deliver up to $100 million in yearly savings. As a result of additional cost saving measures, Babylon expects to deliver an additional 25% in cost reductions on an annualized basis. Babylon continues to expect the proceeds from the planned sale of its IPA business in California to fund the Company to profitability.

Babylon's previously announced revenue guidance was provided under IFRS, and was between $1.05 to $1.1 billion. Babylon has transitioned to U.S. domestic reporting company status as of January 1, 2023. Accordingly, Babylon will report its full Q4 and 2022 year-end results and provide future guidance under U.S. GAAP.

In addition, Babylon announced that Ali Parsa, Founder and Chief Executive Officer, and David Humphreys, Chief Financial Officer, will participate in the 41st Annual J.P. Morgan Healthcare Conference, including a company presentation at 10:30 a.m. Pacific Time on Thursday, January 12, 2023. The live audio webcast of the presentation will be available on the "Events" page of the Investors section of Babylon's website. The replay will remain available for 30 days following the event. For more information, please visit <u>https://ir.babylonhealth.com/</u>.

<u>Non-GAAP Financial Measures</u>

Adjusted EBITDA is a non-GAAP measure under U.S. GAAP and IFRS. IFRS Adjusted EBITDA, which Babylon has reported in prior periods, is defined as profit (loss) for the period, adjusted for finance costs and income, depreciation and amortization, tax provision or benefit, impairment expenses, change in fair value of warrant liabilities, loss on settlement of warrants, share-based compensation, foreign exchange gain or loss, restructuring and other one-time benefit arrangements and gain or loss on sale of subsidiaries.

Babylon is unable to reconcile projected Adjusted EBITDA loss for 2022 to the most directly comparable GAAP measure, as we have not yet completed our financial closing process and are not able to forecast Loss for the period on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in predicting certain items that affect Loss for the period, including, but not limited to, changes in fair value of warrant liabilities, impairment expense, share-based compensation, foreign exchange gains or losses and gains and losses on sale of subsidiaries. Adjusted EBITDA should not be used to predict Loss for the period as the difference between the two measures is variable and may be significant.

We believe that Adjusted EBITDA is a useful metric for investors to understand and evaluate our operating results and ongoing profitability because it permits investors to evaluate our recurring profitability from our ongoing operating activities.

Adjusted EBITDA has certain limitations, and you should not consider it in isolation or as a substitute for analysis of our results of operations as reported under GAAP. We caution investors that amounts

------

presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by other issuers, because some issuers calculate Adjusted EBITDA differently or not at all, limiting its usefulness as direct comparative measure.

<u>About Babylon</u>

At Babylon, our mission is to make quality healthcare accessible and affordable for every person on Earth. We believe that this is possible by combining cutting edge technology with the best medical expertise. To this end we are building an integrated digital first primary care service that can manage population health at scale.

Founded in 2013, we are reengineering how people engage with their care at every step of the healthcare continuum. By flipping the model from reactive sick care to proactive healthcare through the devices people already own, we offer millions of people globally, ongoing, always-on care. And, we have already shown that in environments as diverse as the developed UK or developing Rwanda, urban New York or rural Missouri, for people of all ages, it is possible to achieve our mission by leveraging our highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare.

Today, we support a global patient network across 15 countries, and operate in 16 languages. In 2021 alone, Babylon helped a patient every 6 seconds, with approximately 5.2 million consultations and AI interactions. Importantly, this was achieved with a 93% user retention rate in our NHS GP at Hand service and 4 or 5-star ratings from more than 90% of our users across all of our geographies. We are working to demonstrate how our model of digital first integrated primary care can be applied to manage the health of the population in different settings across Medicare, Medicaid, and commercial value based care contracts in the US and our primary care services in the UK.

Babylon is also working with governments, health providers, employers and insurers across the globe to provide them with a new digital-first platform that any partner can use to deliver high-quality healthcare with lower costs and better outcomes. For more information, please visit visit <u>www.babylonhealth.com</u>.

<u>Forward-Looking Statements</u>

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, without limitation, information concerning Babylon's possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment and potential growth opportunities.

These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Babylon's management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to: our future financial and operating results and ability to generate profits in the future and our timetable to profitability; that we may require additional financing and our ability to obtain additional financing on favorable terms; our ability to sell the Meritage Medical Network/Independent Physician Association business, including the timing of the sale and the sale price; the impact of our recently completed reverse share split on the price and trading

------

market for our Class A ordinary shares; if we fail to comply with the continued listing standards and rules of the New York Stock Exchange (the "NYSE"), the NYSE may delist our Class A ordinary shares; uncertainties related to our ability to continue as a going concern; our ability to successfully execute our planned cost reduction actions and realize the expected cost savings; the growth of our business and organization; risks associated with impairment of goodwill and other intangible assets; our failure to compete successfully; our ability to renew contracts with existing customers, and risks of contract renewals at lower fee levels, or significant reductions in members, pricing or premiums under our contracts due to factors outside our control; our dependence on our relationships with physician-owned entities; our ability to maintain and expand a network of qualified providers; our ability to increase engagement of individual members or realize the member healthcare cost savings that we expect; a significant portion of our revenue comes from a limited number of customers; the uncertainty and potential inadequacy of our claims liability estimates for medical costs and expenses; risks associated with estimating the amount and timing of revenue recognized under our licensing agreements and value-based care agreements with health plans; risks associated with our physician partners' failure to accurately, timely and sufficiently document their services; risks associated with inaccurate or unsupportable information regarding risk adjustment scores of members in records and submissions to health plans; risks associated with reduction of reimbursement rates paid by third-party payers or federal or state healthcare programs; risks associated with regulatory proposals directed at containing or lowering the cost of healthcare, including the ACO REACH model; immaturity and volatility of the market for telemedicine and our unproven digital-first approach; our ability to develop and release new solutions and services; difficulty in hiring and retaining talent to operate our business; risks associated with our international operations, economic uncertainty, or downturns; the impact of COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business; risks associated with foreign currency exchange rate fluctuations and restrictions; and the other risks and uncertainties identified in Babylon's Annual Report on Form 20-F filed with the SEC on March 30, 2022, and in other documents filed or to be filed by Babylon with the SEC and available at the SEC's website at www.sec.gov.

Babylon cautions that the foregoing list of factors is not exclusive and cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, Babylon does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release.

*Media*

<u>press@babylonhealth.com</u>

*Investors*

<u>investors@babylonhealth.com</u>

<br>